Latest / Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals
Lorundrostat: Results from Advance-HTN Phase 2 Study
Luke Laffin, MD, shares the findings from a late breaker he presented at ACC 2025. Lorundrostat is an investigational drug found to significantly lower 24-hour blood pressure among patients with uncontrolled and resistant hypertension.
Learn more about C5 Research at Cleveland Clinic.
https://my.clevelandclinic.org/research/c5research
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.